Position in PRGO
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$5,072,620
+$4,411,240 QoQ
Shares Held
472,311
+894.1% QoQ
Ownership
0.341%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in PRGO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026IMC-Chicago, LLC holds $43,160,180 across 15 Drug Manufacturers - Specialty & Generic names. PRGO ranks #4 (11.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
22,162 | $13,141,622 | |
| 2 | HIMS |
Hims & Hers Health, Inc.
|
508,575 | $10,558,017 | |
| 3 | BCRX |
Biocryst Pharmaceuticals Inc
|
631,290 | $6,009,880 | |
| 4 | PRGO |
PERRIGO Co plc
This page
|
472,311 | $5,072,620 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
89,569 | $2,697,818 | |
| 6 | ZTS |
Zoetis Inc.
|
13,989 | $1,653,639 | |
| 7 | VTRS |
Viatris Inc
|
93,825 | $1,267,575 | |
| 8 | HROW |
Harrow, Inc.
|
21,789 | $768,280 |
All Filings in PRGO
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,072,620 | 472,311 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $661,380 | 47,513 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $685,426 | 30,778 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $278,395 | 10,419 | Shares | Sole | 2025-07-22 | |
| 2024-12-31 | $616,525 | 23,980 | Shares | Sole | 2025-01-27 | |
| 2024-09-30 | $401,764 | 15,317 | Shares | Sole | 2024-10-25 | |
| 2024-06-30 | $681,393 | 26,534 | Shares | Sole | 2024-07-15 | |
| 2024-03-31 | $830,695 | 25,806 | Shares | Sole | 2024-04-12 | |
| 2023-12-31 | $396,296 | 12,315 | Shares | Sole | 2024-02-09 | |
| No filing history on record for this holder in this stock. | ||||||